Free and open · new CVEs checked every 20 minutesStatusRSSOpen dataContact

CVE-2026-66282: In EmberZNet 9.1.1 and earlier, a malformed Publish Billing Period command can result in a recursive function

24
Routine
MEDIUM 6.0

CVE-2026-66282 is a medium-severity flaw (CVSS 6.0) affecting affected software. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.

In EmberZNet 9.1.1 and earlier, a malformed Publish Billing Period command can result in a recursive function call that will never reach its end condition. These messages must come from a device that has already joined the network. Only devices supporting the Price Cluster are impacted.

Why this priority

  • No elevated risk signals yet

No fix is published yet: follow the downgrade or mitigation steps.

Risk facts

CVSS score6.0 (Medium)
Attack vectorNetwork (remote)
Attack complexityLow
Privileges neededLow
User interactionNone
EPSS exploit chance0.2% (top 87%)
CISA exploited listNo
WeaknessCWE-674
Published2026-10-22
Last modified2026-10-23
Publisher (CNA): Silicon Labs

Timeline

Verify at the official source NVD · CVE Program · Report a problem with this page
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.

Quick answers

How do I fix CVE-2026-66282?

No fixed release is listed yet. Watch the vendor advisory and apply any mitigation shown on this page.

Is CVE-2026-66282 being exploited?

CVE-2026-66282 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.

What does CVE-2026-66282 affect?

CVE-2026-66282 affects affected software. Severity is medium (CVSS 6.0). In EmberZNet 9.1.1 and earlier, a malformed Publish Billing Period command can result in a recursive function call that will never reach its end condition. These messages must come from a device that has already joined the network. Only dev

How urgent is CVE-2026-66282?

Priority 24/100. No elevated risk signals yet.

References

← Back to latest CVEs